Please check your internet connection and try again.
# Lorazepam (representative benzodiazepine)
## Overview
Lorazepam is a benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties.
## Primary Indications
* Anxiety disorders
* Insomnia due to anxiety or transient situational stress
* Preoperative sedation
* Management of status epilepticus
## Adult Dosing
* **Anxiety:** 1-3 mg orally every 8-12 hours. Maximum recommended daily dose is not well-defined, but higher doses may be required for severe anxiety.
* **Insomnia:** 2-4 mg orally at bedtime.
* **Preoperative Sedation:** 2-4 mg orally 2 hours before surgery.
* **Status Epilepticus:** 2-4 mg IV/IM, may be repeated after 10-15 minutes if needed. Maximum initial dose is 8 mg. Further doses should be guided by clinical response and physician protocol.
## Pediatric Dosing
* Dosing in pediatric patients is highly variable and requires careful consideration of age, weight, and clinical condition. Specific pediatric dosing recommendations are not universally established and may depend on institutional protocols or specialist guidance.
* **Status Epilepticus:** 0.05-0.1 mg/kg IV/IM up to a maximum of 4 mg per dose. Repeat doses may be administered.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution, may require dose reduction.
* **Renal Impairment:** Use with caution.
* **Elderly:** Initiate with lower doses (e.g., 0.5 mg orally twice daily) and titrate slowly, as elderly patients may be more sensitive to adverse effects.
## Contraindications
* Known hypersensitivity to lorazepam or other benzodiazepines.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
## Adverse Effects
Common: Drowsiness, dizziness, weakness, ataxia, confusion.
Less Common: Sedation, dysarthria, amnesia, depression, paradoxical excitement, hypotension, respiratory depression (especially with IV administration or in combination with other CNS depressants).
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, antihistamines, antipsychotics, other sedative-hypnotics):** Additive CNS depression, increasing the risk of sedation, respiratory depression, coma, and death.
* **Theophylline, Aminophylline:** May reduce the sedative effects of lorazepam.
## Monitoring
* Assess for therapeutic response (reduction in anxiety, improved sleep, cessation of seizures).
* Monitor for adverse effects, particularly sedation, dizziness, confusion, and respiratory status, especially during initiation, dose changes, or with IV administration.
* Monitor for signs of dependence and withdrawal with prolonged use.
## Clinical Pearls
* Lorazepam is a Schedule IV controlled substance.
* IV administration can cause hypotension and respiratory depression; administer slowly and monitor closely.
* Abrupt discontinuation can lead to withdrawal symptoms (anxiety, insomnia, irritability, tremors, nausea, seizures). Taper gradually.
* Effectiveness for long-term anxiety management is limited due to tolerance and dependence.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to verify this information before patient care.*
